Active, not recruitingPhase 2NCT05938036

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

Studying Adult acute respiratory distress syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Aqualung Therapeutics Corp.
Principal Investigator
Stan Miele
Aqualung Therapeutics Corp.
Intervention
ALT-100 mAb(drug)
Enrollment
15 target
Eligibility
18-100 years · All sexes
Timeline
20232027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05938036 on ClinicalTrials.gov

Other trials for Adult acute respiratory distress syndrome

Additional recruiting or active studies for the same condition.

See all trials for Adult acute respiratory distress syndrome

← Back to all trials